LY3537982 Shows Promise in Treating KRAS G12C-Mutated Solid Tumors
According to a report published on OncLive, a Phase 1 trial of the investigational drug LY3537982 has demonstrated promising results in treating advanced solid tumors with KRAS G12C mutations. The trial enrolled 29 patients with various types of cancer, including non-small cell lung cancer and colorectal cancer, who had progressed on standard therapies. The drug was well-tolerated, with only mild to moderate side effects reported. Of the 23 evaluable patients, 2 had a partial response, and 14 had stable disease. The study is ongoing, with further testing planned to assess the drug’s efficacy and safety. LY3537982 is a small molecule inhibitor of KRAS G12C, a mutation that is found in approximately 13% of non-small cell lung cancers and 3-5% of other solid tumors. If successful, the drug could provide a new treatment option for patients with these types of cancers.